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Abstract RXRL is predominantly involved in retinoid responses
in neuroblastoma cells, in particular the N-type SH SY 5Y cells
and the S-type SH S EP cells, both derivatives of a mixed
phenotype neuroblastoma cell line. The aim of this study was to
identify RXRL isoforms expressed in neuroblastoma cells and to
characterise a putative novel RXRL transcript. RXRL1 and
RXRL2 were expressed in these neuroblastoma cells. An isoform
with an insertion into the ligand binding domain, RXRLSLSR
(referred to in previous studies as RXRL3), was expressed at a
similar level to RXRL. A novel RXRL transcript was identified
by RNase protection assays and was at least as abundant as the
expected RXRL transcript and expressed in other cell types.
Evidence suggests that this novel transcript was transcribed from
an internal promoter between exons 5 and 6, contained a retained
intron (intron 6) and was alternatively spliced with and without
the SLSR insertion. These data show that the pattern of RXRL
expression is complex. The relative abundance of the novel
RXRL transcript suggests that it may be an important aspect of
RXRL function or regulation in a range of cell types. ß 2001
Federation of European Biochemical Societies. Published by
Elsevier Science B.V. All rights reserved.
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1. Introduction
RXRs are transcription factors that can act as ligand de-
pendent or ligand independent heterodimer partners for reti-
noic acid receptors (RARs) and other nuclear receptors [1]. Of
the three RXRs (K, L, Q) that have been characterised, RXRL
was originally identi¢ed as a protein able to bind to the reg-
ulatory region II of the murine major histocompatibility com-
plex (MHC) class I promoter and referred to as H2RIIBP [2].
The human RXRL gene has been mapped to the short arm or
centromeric region of chromosome 6 (6pter^q13) which also
contains the MHC I locus [3]. Two major RXRL isoforms in
the mouse, designated RXRL1 and RXRL2 (GenBank acces-
sion numbers D21830 and D21831), di¡er in the N-terminal
(A) domain with RXRL1 containing an extra 72 amino acids.
These isoform mRNAs are transcribed from two CpG island
promoters and the di¡erent N-terminal exons are spliced to
exons common to both isoforms from the remainder of the
gene [4].
Although the two mouse RXRL isoforms have been char-
acterised in some detail, less information is available about
their human counterparts. The human sequence referred to as
hRXRL2 [5] corresponds to the mRXRL1 isoform [3,6] and is
well conserved across species, except that hRXRL2 contains
two additional in-frame ATG initiator codons which may
serve as alternative translational start sites [3,6]. Since the
human RXRL2 and mouse RXRL1 sequences appear to be
very similar, a putative human RXRL1 isoform can be iden-
ti¢ed by aligning the mouse RXRL2 sequence to the genomic
hRXRL sequence. A third isoform, referred to as hRXRL3 by
its discoverers, contains an in-frame insertion of four amino
acids (SLSR) in the ligand binding domain at codon 419 and
is generated by use of an alternative 3P-splice acceptor site [7].
The same insertion has been found in mouse RXRL [8]. It has
not yet been established whether the N-terminal end of
RXRL3 is identical to that of the L1 or L2 isoform, or has
an alternative sequence. For this reason, we use the super-
script SLSR to indicate transcripts encoding the 12 bp inser-
tion isoform as in RXRLSLSR or RXRL2SLSR. Since the ex-
pression of di¡erent RXR isoforms appears to be well
conserved between species, each receptor isoform may hold
a speci¢c role in retinoid signalling. However, many RXR
expression studies have not recognised the importance of es-
tablishing which RXR isoforms are expressed in a particular
system. RXRL is predominantly involved in retinoid re-
sponses in the N-type SH SY 5Y and the S-type SH S EP
neuroblastoma cells [9], both derivatives of a mixed phenotype
neuroblastoma cell line. The aim of this study was to identify
the RXRL isoforms expressed in these neuroblastoma cells
and to characterise a putative novel RXRL transcript.
2. Materials and methods
2.1. Cell culture and treatment with retinoic acid isomers
SH SY 5Y and SH S EP neuroblastoma cells [10], SK23 melanoma
cells [11], HEP G2 hepatoblastoma cells, A431 epithelial cells (Euro-
pean Collection of Animal Cell Cultures, Porton Down, UK) and
human ¢broblast cells [12] were grown in Dulbecco’s modi¢ed Eagle’s
medium (Hyclone-Europe, Tyne and Wear, UK) supplemented with
10% foetal calf serum (Sera Labs, Crawley, UK) in a humidi¢ed
atmosphere of 5% CO2 in air. For some experiments 8U106 cells
were treated with 1 WM 9-cis-retinoic acid or all-trans-retinoic acid
for 6^24 h, as described previously [13].
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2.2. Extraction of cytoplasmic RNA and RNase protection assays
Total cytoplasmic RNA for RNase protection assays was prepared
using a mini-prep method [14]. RNA from mouse dorsal root ganglion
cells was provided by Dr. Z. Chrzanowska-Lightowlers. Probes for
RNase protection assays were generated using T7 or T3 RNA poly-
merase and cytidine 5P-[K-32P]triphosphate (speci¢c activity 30 TBq/
mmol). The RXRL probe, giving a 570 nucleotide (nt) protected frag-
ment when hybridised to RXRL mRNA, was prepared by sub-cloning
the full-length hRXRL2 cDNA from pTL1-RXRL [5] into Bluescript
KS and linearising with BamHI. The hRXRL plasmid used for these
studies, pTL1-RXRL [5], was found, on re-sequencing, to contain the
12 bp insert in the ligand binding domain described by Mahajna et al.
[7]. We therefore refer to this cDNA as RXRL2SLSR. As a positive
control for hRXRL, sense transcripts were prepared from XbaI line-
arised plasmid to give a 440 nt protected fragment when hybridised to
the antisense RXRL2SLSR probe. PCR fragments cloned into the
pCR2.1-TOPO vector were linearised with PstI, PmeI or NotI and
used to make sense (control) and antisense riboprobes from the T7
RNA polymerase promoter. RNase protection assays were performed
on 10 Wg cytoplasmic RNA using the Ambion RNase protection assay
kit (Ambion, AMS Biotechnology, Oxford, UK) according to the
manufacturer’s instructions [15], and the products separated through
denaturing polyacrylamide gels. In all experiments, RNA size markers
ranging from 100 to 500 nt were prepared from linearised plasmids
(0.5 Wg Century1 size markers per assay, Ambion) containing T7
RNA polymerase promoters. These markers were prepared in parallel
with the experimental probes and acted as standards with respect to
the intensities of protected fragments.
2.3. Preparation of nuclear extracts
Con£uent cells were washed once in ice-cold phosphate bu¡ered
saline (PBS, Sigma, Poole, UK), scraped o¡ into ice-cold PBS and
centrifuged at 13 000Ug for 5 min at 4‡C. Cells were lysed in 100 Wl of
ice-cold lysis bu¡er (20 mM HEPES, pH 7.9, 1 mM EDTA, 0.2%
NP40, 1 mM dithiothreitol [DTT], 1 mM protease inhibitor E64,
1 mM benzamidine, 1 mM leupeptin and 1 mM freshly added phenyl-
methylsulphonyl £uoride) and centrifuged at 5000Ug for 5 min at
4‡C. The nuclear pellet was re-suspended in 100 Wl of high salt bu¡er
(as for lysis bu¡er but without 0.2% NP40, and with 20% glycerol and
420 mM NaCl) and incubated for 2 h on ice before centrifugation at
13 000Ug for 2 min. The resulting supernatant (nuclear extract) was
frozen rapidly and stored at 380‡C. Protein concentration was deter-
mined using the Bio-Rad protein assay (Bio-Rad, Hemel Hempstead,
UK).
2.4. Western blotting
For Western blotting 20 Wg of nuclear protein was separated by
electrophoresis through a 10% sodium dodecyl sulphate^polyacryl-
amide gel (SDS^PAGE) at 100 V and transferred to nitrocellulose
(Bio-Rad) membrane at 4‡C and 30 V overnight. Membranes were
blocked with blocking solution (5% w/v skimmed powdered milk, in
Tris-bu¡ered saline [TBS] with 0.05% Tween 20 pH 8.0), and probed
with rabbit antibodies speci¢c for the N-terminal region of human
RXRL1, human RXRL2 (Santa Cruz Biotechnology, Santa Cruz,
CA, USA), or a pan-RXR monoclonal antibody (4RX-1D12, a gift
from Pierre Chambon), diluted in blocking solution. Membranes were
subsequently washed in TBS/Tween for 30 min, and then incubated
for 1 h with biotinylated anti-rabbit IgG (Amersham Pharmacia),
diluted 1 in 500 in blocking solution. After a ¢nal 30 min wash,
membranes were agitated for 1 h in a 1 in 500 dilution of streptavi-
din^biotinylated horseradish peroxidase complex (Amersham Phar-
macia) and developed using an enhanced chemiluminescence (ECL)
detection kit (Amersham Pharmacia) and Fuji X-ray ¢lm.
2.5. Reverse transcription (RT)-polymerase chain reaction (PCR)
To generate cDNA, 1.5 Wg of total cellular RNA, 2 Wl of oligo(dT)
(0.5 Wg/Wl) (Amersham Pharmacia) and RNase-free water to a ¢nal
volume of 10 Wl were mixed and incubated at 70‡C for 10 min and
cooled on ice. To each tube, 2 Wl of 0.1 M DTT, 1 Wl of 10 mM
dNTPs, 1 Wl of RNasin and 5 Wl of Superscript II reaction bu¡er (Life
Technologies, Paisley, UK) were added, mixed and heated to 37‡C for
2 min followed by the addition of 400 U of Superscript II (Life
Technologies). The reaction was incubated at 37‡C for 1 h and this
template cDNA used for PCR. Primers (50 pmol) were added to 5 Wl
of reaction IV bu¡er and 5 Wl of MgCl2 (both Abgene, Epsom, UK)
to a ¢nal volume of 50 Wl. A wax pellet was added and the tubes
heated to 70‡C for 1 min and cooled on ice. Template cDNA (5 Wl) or
genomic DNA with 5 Wl of reaction IV bu¡er, 5 Wl of MgCl2 and 1 Wl
of Red Hot DNA polymerase (Abgene) in a total volume of 50 Wl was
laid over the wax. The reaction was placed in a PCR machine (Sanyo
Gallenkamp, Loughborough, UK) for 30 cycles of 1 min at 95‡C,
1 min at 60‡C and 1 min at 72‡C. PCR products were resolved by
electrophoresis through 8% polyacrylamide gels and stained with sil-
ver nitrate. Primers used in these reactions are shown in Table 1.
2.6. Cloning of PCR products
PCR products were cloned into pCR 2.1-TOPO cloning vector
following instructions provided by the manufacturer (Invitrogen, Gro-
ningen, The Netherlands). Colonies of transformed cells were grown
up as 10 ml cultures overnight and plasmid DNA prepared using
Qiagen kits (Qiagen, Crawley, UK) according to the manufacturer’s
instructions. Plasmid DNA was sequenced by the Newcastle Univer-
sity Facility for Molecular Biology using an Applied Biosystems
(Warrington, UK) sequencer.
2.7. Transfections
RXRL2SLSR stable transfectants were established using the tetracy-
Fig. 1. Western blot analysis of RXRL1 and -L2 expression in SH
SY 5Y and SH S EP cells. A: Expression of RXRL2 in SH SY 5Y
and SH S EP cells detected with a rabbit polyclonal antibody. B:
Expression of RXRL1 in SH SY 5Y and SH S EP cells. C, control;
9C, 1 WM 9-cis-retinoic acid; AT, 1 WM all-trans-retinoic acid. C:
Western blot analysis of nuclear protein from SH SY 5Y cells stably
transfected with a tetracycline inducible RXRL2SLSR construct. C,
transfected cells without treatment (vehicle control); Tet, transfected
cells treated with 100 Wg/ml tetracycline for 24 h to induce expres-
sion of the RXRL2SLSR construct. D: Expression of RXRL2,
RXRL1 and RXRL detected with rabbit polyclonal antibodies, and
a pan-RXRL monoclonal antibody, in SH SY 5Y cells and A431
cells. For all panels: M = molecular weight marker.
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cline regulated (T-rex) expression system which consisted of the
pcDNA6/TR and pcDNA4/TO vectors (Invitrogen). The pcDNA6/
TR vector, which constitutively expresses the TetR, had previously
been stably transfected into SH SY 5Y cells (unpublished data).
The pcDNA4/TO vector was ligated with full-length RXRL2SLSR
cDNA and transfected using Super Transfection reagent (Qiagen)
into the pcDNA6/TR transfected SH SY 5Y cells. Transfected colo-
nies/cells were maintained with 5 Wg/ml of blastocydin and 500 Wg/ml
zeocin.
2.8. Data analysis
Genomic sequence data for RXRL were from GenBank accession
number AF065396 and base numbers refer to positions within this
sequence. To identify additional splice donor/acceptor and promoter
sites within the RXRL genomic sequence and to con¢rm alternative
splicing sites, MatInspector and the neural network promoter predic-
tion program by Martin Reese [16] were used.
3. Results
3.1. N-terminal RXRL isoforms in neuroblastoma cells
To identify the N-terminal RXRL1 and RXRL2 isoforms,
Western blots of nuclear protein from control, 9-cis- and all-
trans-retinoic acid treated SH SY 5Y and SH S EP cells were
probed with antibodies speci¢c for RXRL1 and L2 N-terminal
regions. For both cell types, the RXRL2 antibody gave a
strong band at the appropriate molecular weight (Fig. 1A).
Conversely, the RXRL1 antibody produced a faint band, just
detectable in both cell types (Fig. 1B). 9-cis-Retinoic acid or
all-trans-retinoic acid had no apparent e¡ect on the level of
RXRL1 or -L2 protein. To verify the speci¢city of the RXRL2
antibody, Western blots of nuclear extract from tetracycline
induced and non-induced SH SY 5Y cells stably transfected
with a tetracycline inducible hRXRL2SLSR construct were
probed with the RXRL2 antibody. An increase in RXRL2
signal (detected as two bands) was obtained for the nuclear
extract from tetracycline induced cells, compared to the con-
trol cells (Fig. 1C). The fact that both RXRL2 bands were
increased in the tetracycline induced cells may have resulted
from translation of hRXRL2 from two translational start sites
[6]. A431 cells express both RXRL1 and RXRL2 (in-house
testing, Santa Cruz Biotechnology), and were used as a pos-
itive control for RXRL1. Relative to A431 cells, SH SY 5Y
cells expressed RXRL protein at a lower level overall, but
RXRL2 was relatively more predominant than RXRL1 in
SH SY 5Y cells (Fig. 1D).
3.2. Expression of RXRLSLSR in neuroblastoma cells
To determine whether RXRLSLSR was expressed in SH SY
5Y and SH S EP cells, RT-PCR experiments were carried out
with cytoplasmic RNA using primers MHF and MHR (Table
1) [7]. Products of 128 bp and 140 bp (Figs. 2 and 3), corre-
sponding to the sizes predicted for the normal RXRL and 12
bp insertion RXRLSLSR isoforms respectively, were obtained.
Three fainter bands of sizes between 298 and 157 bp were also
detected; the identity of these additional bands is unknown
but the largest of these could have resulted from genomic
DNA contamination or the presence of unprocessed tran-
scripts. These results suggest that the RXRL isoforms in SH
SY 5Y and SH S EP cells are expressed with (RXRLSLSR) and
without (RXRL) the 12 bp insertion.
Fig. 2. Schematic diagram of hRXRL genomic sequence to indicate the identity of the bands arising from RT-PCR using the various primer
pairs speci¢ed in the text. The RXRL riboprobe and the exons it encompasses are indicated at the top of the diagram. The start and end of
each exon are indicated as numbered in the sequence of GenBank accession number AF065396.
Table 1
Primer sequences used in RT-PCR
Name Basea Sequence
MHFb 5668^5688 ATGTTCGAGATGGCATCCTC
MHRc 5892^5911 CCAAAATGCGTGACATGAGG
BDF 4834^4856 AACAGAAGAGTGACCAGGGCGTT
BDR 5715^5738 CAACTCAGCCCATTCAGCAGGAGT
RXRLEx6 5371^5392 CACTTTTCCTCCTTGCCTCTGG
aBase sequence as in GenBank accession number AF065396.
bPrimer hRXRL1286 of Mahajna et al. [7].
cPrimer hRXRL1416 of Mahajna et al. [7].
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3.3. RNase protection assays using a 3P-RXRL2SLSR probe
In RNase protection assays, two prominent bands resulted
from the use of a RXRL2SLSR 3P-end probe: the predicted 570
nt band complementary to the probe and corresponding to
RXRLSLSR mRNA, and a more intense band of approxi-
mately 455 nt (Fig. 4). Since hybridisation of the RXRL2SLSR
3P-end probe to RXRL mRNA would result in a smaller frag-
ment of approximately 355 nt, the 455 nt fragment could not
be accounted for by the 12 bp insertion. Furthermore, the 570
nt and 455 nt protected fragments were also observed when
¢broblast, melanoma cell and mouse dorsal root ganglion cell
RNA was used in RNase protection assays, implying that the
novel 455 nt fragment was not unique to neuroblastoma cells
(Fig. 4B). A small (1.9-fold) but consistent induction of the
570 and 455 nt fragment was observed in SH SY 5Y cells
treated with retinoic acid (Fig. 4). To investigate the possibil-
ity that the 455 nt band resulted from alternative splicing, the
genomic RXRL sequence was screened for splice donor/accep-
tor and promoter sites involving the 3P- or 5P-end of the
mRNA complementary to the riboprobe sequence. In addi-
tion to the intron/exon boundaries consistent with the hRXRL
cDNA sequence (Fig. 2), there was a high probability (0.95)
alternative acceptor site present in the genomic sequence cor-
responding to the 5P-end of the mRNA complementary to the
RXRL2SLSR riboprobe (Fig. 2). Alternative splicing at this site
would splice exon 6 to within exon 7, missing 75 bases at the
5P-end of exon 7, but retaining the correct reading frame. To
test this idea, primers (BDF and BDR, Table 1) were designed
to amplify the putative novel RXRL transcript by RT-PCR.
However, RT-PCR experiments with these primers using cy-
toplasmic RNA from SH SY 5Y cells produced the 305 bp
band (Fig. 3) predicted for RXRL or RXRLSLSR but not a 230
bp band predicted for the putative novel transcript.
Possible internal promoters were identi¢ed between exons 5
and 6 (probability score 0.90 and 0.99 for bases 4946^4996
and 5190^5240 respectively, Fig. 2). If an RXRL transcript
were generated from one of these internal promoters, the
BDF (exon 5) and BDR (exon 7) primer pair would not am-
plify the cDNA of a transcript in which the donor site of exon
6 was spliced to the alternative acceptor in exon 7. Therefore,
RT-PCR was repeated using a primer (Ex 6) in exon 6, down-
stream of these internal promoters, together with the MHR
primer (Table 1). RT-PCR of cytoplasmic RNA from SH SY
5Y cells produced six bands ranging from approximately 517
bp to 228 bp in size (Fig. 5A). The uppermost band (approx-
imately 517 bp) was due to genomic DNA contamination and
the lower two bands of sizes 240 bp and 228 bp corresponded
Fig. 3. Silver stained polyacrylamide gels showing RT-PCR products
using the BDF, BDR and MHF, MHR primer sets to identify the
presence of the RXRLSLSR isoform and a potential alternatively
spliced RXRL transcript. The ¢rst two lanes (from the left, M) are
di¡erent molecular weight markers, and sizes (bp, left side of ¢gure)
are given for the markers in the ¢rst lane only. Components of the
PCR reactions loaded into each lane are indicated on the ¢gure;
controls were without Superscript reverse transcriptase (3ss), and
without cDNA (3cDNA). Sizes of relevant PCR products are indi-
cated on the right of the ¢gure.
Fig. 4. RNase protection assay for RXRL. A: RNase protection as-
say in SH SY 5Y and SH S EP neuroblastoma cells showing the
570 nt, 455 nt and 355 nt protected fragments (probe length 616 nt).
The cells were treated (Treatment) with control ethanol (C), 1 WM
9-cis-retinoic acid (9C) or 1 WM all-trans-retinoic acid (AT) for 6 h
or 24 h (Hours). B: RNase protection assay, using a cloned human
genomic DNA fragment as a riboprobe template (lanes 1^8), in neu-
roblastoma cells, human melanoma cells (SK23), and human ¢bro-
blasts (¢broblasts). A protected fragment of approximately 650 nt
was detected in these cells, and a fragment of approximately 940 nt
representing undigested probe. Lanes 9^15, RNase protection assay
using RXRL2SLSR 3P-end (as in A) riboprobe using neuroblastoma
cells, human melanoma cells (SK23), human ¢broblasts (¢broblasts)
and mouse dorsal root ganglion RNA. M, marker RNA.
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to RXRLSLSR and RXRL respectively. Of the three remaining
bands, a PCR product of approximately 440 bp was partic-
ularly prominent and was therefore cloned. Four clones, with
inserts of the appropriate size were sequenced and alignment
of the 440 bp PCR fragment sequence to the genomic RXRL
sequence indicated that the PCR product included the intron
between exon 6 and exon 7 (Fig. 2) and that two of the clones
had the 12 bp (SLSR) insertion (441 bp) and two did not (429
bp). A transcript with this structure would give a predicted
455 nt protected fragment on RNase protection assays with
the hRXRL2SLSR 3P-end probe.
To verify that transcripts with this structure were expressed,
RNase protection assays were carried out in parallel using
riboprobes prepared from two clones of the 440 bp PCR
product (clones 14pp and 20pp with and without 12 bp in-
sertion) to probe cytoplasmic RNA from SH SY 5Y, SH S EP
neuroblastoma cells, and SK23 melanoma cells. Protected
fragments of appropriate sizes were observed (Fig. 5B), con-
¢rming the presence of RXRL transcripts with an intron se-
quence with and without the SLSR insertion (termed
RXRLint6SLSR and RXRLint6 respectively) in the sample
RNA. Since the 14pp and 20pp probes were prepared and
used in parallel, these results also suggested that both tran-
scripts were expressed at similar levels. Furthermore, the fact
that the protected fragments were of similar or slightly greater
intensity than the 500 nt marker suggest that the complemen-
tary transcripts were roughly comparable in abundance to
transcripts detected with the 3P-RXRL2SLSR probe (Fig. 4).
3.4. Human genomic DNA RNase protection assays
To obtain further evidence that the RXRLint6 and
RXRLint6SLSR transcripts were transcribed from an internal
promoter between exons 5 and 6, a genomic DNA fragment
corresponding to bases 4843^5747 (GenBank accession num-
ber AF065396) was ampli¢ed by PCR from a human blood
sample using BDF and BDR primers (Table 1) and cloned
into pCR2.1 TOPO. After sequence veri¢cation, the PCR
product insert was used as a riboprobe in RNase protection
assays. In addition to undigested probe (940 nt), a protected
fragment of approximately 650 nt was detected (Fig. 4B). As a
positive control, sense RNA from this clone was also prepared
and this hybridised with the riboprobe to give a predicted
fragment size of approximately 900 nt (data not shown).
These results are consistent with a transcriptional start site
between exons 5 and 6. A search of the human genome data-
base with the RXRL intronic region gave only a single match
to chromosome 6, suggesting that this novel transcript was
speci¢c to RXRL and not a product of a pseudogene.
4. Discussion
Multiple isoforms have been reported for all members of
the nuclear hormone receptor superfamily, including the
RARs and RXRs. We have shown that RXRL is the main
RXR type expressed in SH SY 5Y and SH S EP neuroblas-
toma cells [9] and the results of the present experiments sug-
gest that RXRL and RXRLSLSR transcripts are expressed in
SH SY 5Y and SH S EP neuroblastoma cells. RXRLSLSR is
expressed in a variety of mouse tissues and human tumour cell
lines; Mahajna et al. [7] reported that the level of RXRLSLSR
compared to RXRL varied widely from one RNA source to
another but the signi¢cance of these di¡erences remains un-
known. Although an accurate quantitative comparison of
RXRL isoforms was not made in this study, both RXRL
and RXRLSLSR appeared to be expressed at comparable levels
in SH SY 5Y and SH S EP neuroblastoma cells. It is not
known if the SLSR insertion is present in both RXRL1 and
RXRL2 transcripts.
Con£icting results for the functional role of RXRLSLSR
with respect to DNA binding capacity and heterodimerisation
ability have been reported [7,8]. Mahajna et al. [7] concluded
that RXRK/LSLSR chimeras behaved in a dominant negative
fashion and failed to bind ligand or DNA, and was not active
in forming heterodimers with RARK, although was capable of
forming homodimers with RXRK. Thus the SLSR insertion
apparently a¡ected ligand binding properties as well as hetero-
dimerisation functions. Fujita and Mitsuashi [8] reported
that mouse RXRLSLSR also failed to bind ligand with high
a⁄nity, or to bind to RXREs in the presence or absence of
9-cis-retinoic acid, but did form heterodimers with TRK and
Fig. 5. A: Silver stained polyacrylamide gel showing RT-PCR prod-
ucts using the Ex 6 and MHR primer pair. The ¢rst two lanes
(from the left, M) are di¡erent molecular weight markers; sizes (bp)
are shown for the markers in the ¢rst lane only. Components of the
PCR reaction loaded into each lane are indicated on the ¢gure:
controls were without Superscript reverse transcriptase (3ss), and
without cDNA (3cDNA). The bands present in the 3ss control
lane are genomic DNA and a product from the pTL1 (RXRL2SLSR)
plasmid DNA (lower band) present as contaminants. B: RNase pro-
tection assays to demonstrate the presence of a novel RXRL tran-
script containing an intronic region (RXRLint6), with and without
the 12 bp insertion, in SH SY 5Y, SH S EP neuroblastoma cells
and SK 23 melanoma cells. Probes were prepared from the 14pp
(probe length 520 nt) and 20pp (probe length 508 nt) clones, with
and without the 12 bp insertion, respectively. M, marker track
showing the 500 nt marker.
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RARK. Clearly the RXRLSLSR isoform has a potential regu-
latory role in the cell, either as a dominant negative receptor
or as a protein that represses the action of other receptors by
preventing their binding to DNA.
The pattern of expression of RXRL is clearly more complex
than has been realised. The experiments reported here gave
evidence that the 455 bp RXRL transcript observed with
RNase protection assays corresponded to the 3P-end of
RXRL but was initiated from a promoter between exons 5
and 6, included a retained intron and was alternatively spliced
to give isoforms with and without the SLSR insertion.
Although these RXRLint6 transcripts were clearly abundant,
perhaps more so than RXRLSLSR and RXRL transcripts, and
were major RNA species in melanoma cells, ¢broblast cells
and mouse ganglion cells, it is unclear whether these are trans-
lated into functional proteins. Translation of the RXRLint6
and RXRLint6SLSR transcripts in all three reading frames gave
the carboxy-terminal end of RXRL, incorporating only part
of the ligand binding domain with a predicted molecular
weight of 15 kDa, as the largest open reading frame. If such
a protein is expressed in neuroblastoma cells it may act in a
dominant negative manner and could be of biological signi¢-
cance.
A number of studies have identi¢ed alternative transcripts
from various genes, but few have reported evidence that these
transcripts are translated into functional proteins. Lu et al.
[17], have identi¢ed a number of splice forms of the tumour
suppressor gene BRAC-1 in both malignant and non-malig-
nant breast epithelial cells. These splice variants are predicted
to encode 80^85 kDa BRAC-1 derived proteins lacking ap-
proximately 60% of the internal amino acids of full length
BRAC-1. Furthermore, alternative transcripts of the gene
for human thrombospondin 2, an extracellular glycoprotein,
have been shown to undergo exon skipping and/or retain in-
trons [18]. A similar event occurs with the glycine receptor
subunit K-3 gene whereby splice events allow a large intronic
sequence to remain in the 3P-untranslated region [19]. Thus,
the expression of alternative transcripts that contain intronic
sequences is not unusual. Further work is needed to establish
the functional role, if any, of the novel RXRL transcript,
although its relative abundance at the message level suggests
that it may be important in regulating RXRL function in a
range of cell types.
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